These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 10875459)
21. PSA kinetics and PSA bounce following permanent seed prostate brachytherapy. Crook J; Gillan C; Yeung I; Austen L; McLean M; Lockwood G Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):426-33. PubMed ID: 17869662 [TBL] [Abstract][Full Text] [Related]
22. Dosimetric parameters as predictive factors for biochemical control in patients with higher risk prostate cancer treated with Pd-103 and supplemental beam radiation. Orio P; Wallner K; Merrick G; Herstein A; Mitsuyama P; Thornton K; Butler W; Sutlief S Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):342-6. PubMed ID: 17236959 [TBL] [Abstract][Full Text] [Related]
23. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer. Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471 [TBL] [Abstract][Full Text] [Related]
24. PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure: a study of 295 patients with a minimum 3-year followup. Toledano A; Chauveinc L; Flam T; Thiounn N; Solignac S; Timbert M; Rosenwald JC; Cosset JM Brachytherapy; 2006; 5(2):122-6. PubMed ID: 16644467 [TBL] [Abstract][Full Text] [Related]
25. Prostate-specific antigen 'bounce' after permanent 125I-implant brachytherapy in Japanese men: a multi-institutional pooled analysis. Satoh T; Ishiyama H; Matsumoto K; Tsumura H; Kitano M; Hayakawa K; Ebara S; Nasu Y; Kumon H; Kanazawa S; Miki K; Egawa S; Aoki M; Toya K; Yorozu A; Nagata H; Saito S; Baba S BJU Int; 2009 Apr; 103(8):1064-8. PubMed ID: 19040526 [TBL] [Abstract][Full Text] [Related]
26. Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features. Dattoli M; Wallner K; True L; Cash J; Sorace R Cancer; 2007 Aug; 110(3):551-5. PubMed ID: 17577217 [TBL] [Abstract][Full Text] [Related]
27. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Sarosdy MF Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557 [TBL] [Abstract][Full Text] [Related]
28. Permanent prostate brachytherapy for Japanese men: results from initial 100 patients with prostate cancer. Okaneya T; Nishizawa S; Nakayama T; Kamigaito T; Hashida I; Hosaka N Int J Urol; 2007 Jul; 14(7):602-6. PubMed ID: 17645602 [TBL] [Abstract][Full Text] [Related]
29. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy. Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872 [TBL] [Abstract][Full Text] [Related]
38. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Ragde H; Korb LJ; Elgamal AA; Grado GL; Nadir BS Cancer; 2000 Jul; 89(1):135-41. PubMed ID: 10897010 [TBL] [Abstract][Full Text] [Related]
39. Six year experience of external beam radiotherapy, brachytherapy boost with a 1Ci (192)Ir source, and neoadjuvant hormonal manipulation for prostate cancer. Izard MA; Haddad RL; Fogarty GB; Rinks A; Dobbins T; Katelaris P Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):38-47. PubMed ID: 16904516 [TBL] [Abstract][Full Text] [Related]
40. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy. Lee HK; Adams MT; Motta J Brachytherapy; 2008; 7(1):17-21. PubMed ID: 18201939 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]